Skip to main content

Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis



Adalimumab and golimumab are subcutaneously administered anti-tumor necrosis factor α (TNFα) biologics used in the treatment of ulcerative colitis (UC). To date, no studies have directly compared treatment patterns and healthcare resource utilization (HRU) among patients with UC receiving these therapies in a real-world setting. The objective of this study was to compare these outcomes among patients with UC treated with either adalimumab or golimumab using a US claims database.


Patients with UC treated with golimumab or adalimumab were identified using the US Optum Clinformatics® Data Mart database. Outcomes of interest included treatment patterns (discontinuations, dose optimizations, persistence, and concomitant medication use) and HRU (outpatient office visits, emergency room [ER] visits, and inpatient stays). Propensity score matching (PSM) was used to account for differences in confounding variables between groups.


Overall, 990 patients were identified (golimumab: n = 277; adalimumab: n = 713). After PSM, 246 patients were included in each group. There were no significant differences between the adalimumab and golimumab groups over the full follow-up period in terms of treatment discontinuations (53.7% vs. 51.2%; P = 0.5881), dose optimizations (35.4% vs. 39.4%; P = 0.3515), or persistence (338.2 vs. 361.2 days; P = 0.4194). During the year after initiating therapy, there were no significant differences in concomitant immunosuppressant (21.9% vs. 21.7%; P = 0.9686) or corticosteroid use (74.7% vs. 78.8%; P = 0.3573) or in HRU outcomes including outpatient office visits (93.3% vs. 94.0%; P = 0.7660), ER visits (15.2% vs. 10.9%; P = 0.2238), and inpatient stays (15.2% vs. 13.6%; P = 0.6680).


In this nationwide PSM cohort study of patients with UC receiving golimumab or adalimumab, no significant differences were observed between groups for treatment patterns or HRU outcomes. High rates of concomitant corticosteroid use, treatment discontinuations, and HRU while on therapy highlight key unmet needs in the treatment of UC.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70.

    Article  Google Scholar 

  2. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of crohn’s disease and ulcerative colitis in olmsted county, minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–63.

    Article  Google Scholar 

  3. Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by US children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):62–8.

    Article  Google Scholar 

  4. Cohen R, Skup M, Ozbay AB, et al. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015;18(6):447–56.

    Article  Google Scholar 

  5. Perera S, Yang S, Stott-Miller M, Brady J. Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and crohn’s disease. J Health Econ Outcomes Res. 2018;6(1):96–112.

    Article  Google Scholar 

  6. Long GH, Tatro AR, Oh YS, Reddy SR, Ananthakrishnan AN. Analysis of safety, medical resource utilization, and treatment costs by drug class for management of inflammatory bowel disease in the united states based on insurance claims data. Adv Ther. 2019;36(11):3079–95.

    Article  Google Scholar 

  7. Chang S, Hudesman D. First-line biologics or small molecules in inflammatory bowel disease: a practical guide for the clinician. Curr Gastroenterol Rep. 2020;22(2):7.

    Article  Google Scholar 

  8. Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509-21.e5.

    Article  Google Scholar 

  9. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.

    Article  Google Scholar 

  10. Feagan BG, Lémann M, Befrits R, et al. Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis. 2012;18(1):152–60.

    Article  Google Scholar 

  11. Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.

    PubMed  Google Scholar 

  12. Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–27.

    Article  Google Scholar 

  13. Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS ONE. 2017;12(4):e0175099.

    Article  Google Scholar 

  14. Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20(6):752–61.

    Article  Google Scholar 

  15. Singh S, Heien HC, Sangaralingham LR, et al. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2016;43(9):994–1003.

    Article  CAS  Google Scholar 

  16. Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215–26.

    Article  CAS  Google Scholar 

  17. Flasar MH, Cross RK. What is the need for comparative effectiveness studies in IBD? Expert Rev Gastroenterol Hepatol. 2014;8(8):851–4.

    Article  CAS  Google Scholar 

  18. Ye Y, Manne S, Bennett D. Identifying patients with inflammatory bowel diseases in an administrative health claims database: do algorithms generate similar findings? Inquiry. 2019;56:46958019887816.

    PubMed  Google Scholar 

  19. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.

    Article  Google Scholar 

  20. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179-91.e6.

    Article  CAS  Google Scholar 

  21. Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229-39.e5.

    Article  CAS  Google Scholar 

  22. Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17(1):7–19.

    Article  Google Scholar 

  23. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–84.

    Article  Google Scholar 

  24. Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8:212572.

    Article  Google Scholar 

  25. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):769-808.e29.

    Article  Google Scholar 

  26. Comerford E, DiBonaventura M, Smith T, et al. Real-world effectiveness of biologic therapies among patients with moderate-to-severe ulcerative colitis in the United States. Am J Gastroenterol. 2019;114(Supplement 1):S7.

    Google Scholar 

  27. Koliani-Pace JL, Singh S, Luo M, et al. Changes in vedolizumab utilization across US academic centers and community practice are associated with improved effectiveness and disease outcomes. Inflamm Bowel Dis. 2019;25(11):1854–61.

    Article  Google Scholar 

  28. Long MD, Smith TW, DiBonaventura M, et al. Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the united states. Inflamm Bowel Dis. 2020;26(6):941–8.

    Article  Google Scholar 

  29. Christensen B, Colman RJ, Micic D, et al. Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety. Inflamm Bowel Dis. 2018;24(4):849–60.

    Article  Google Scholar 

  30. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283x17750355.

    Article  Google Scholar 

  31. Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–79.

    Article  CAS  Google Scholar 

  32. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69-81.e3.

    Article  Google Scholar 

  33. Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 2020;15(1):e0227914.

    Article  CAS  Google Scholar 

  34. Rubin D, Mody R, Wang CC, Davis K. Assessment of therapy changes and drug discontinuation among ulcerative colitis patients using health claims data. Am J Gastroenterol. 2012;1:S678–9.

    Article  Google Scholar 

Download references



This study as well as the journal’s Rapid Service fee were funded by Janssen Inc.

Medical Writing and Editorial Assistance

The authors wish to thank Dr. Ari Mendell, Dana Anger, and Coby Martin of EVERSANA Value and Evidence for their support in the development of this manuscript. This support was funded by Janssen Inc.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authors’ Contributions

Michael J. Stewart, Talat Bessissow, James Gregor, Maureen Hazel, and Bernie Sattin contributed to the conception and design of the study. All authors contributed to the interpretation of data for the study. The first draft of the manuscript was written by Tracy S.H. In, Kinda Karra, and Bernie Sattin with the support of EVERSANA. All authors provided critical revision for important intellectual content. All authors read and approved the final manuscript.

Prior Presentation

The analysis and data reported in this manuscript were previously presented at the following congresses: Stewart et al. Su1874. Presented at the Digestive Disease Week 2019; May 18–21, 2019.


Michael J. Stewart has received research support from AbbVie, Takeda, Janssen, Genentech and Gilead and honoraria from Janssen, Takeda, AbbVie, Pfizer, Amgen and Sandoz. Talat Bessissow has received honoraria and/or grants from AbbVie, BMS, Ferring, Gilead, Janssen, Merck, Pfizer, Roche, Sandoz and Takeda. James Gregor reports participating in advisory boards and receiving research support from Janssen, AbbVie, Takeda and Pfizer. Maureen Hazel is currently an employee of Janssen Inc. Tracy S.H. In is currently an employee of Janssen Inc. Kinda Karra was an employee of Janssen Inc. at the time of manuscript development and is currently an employee of Merck Canada Inc. Dorota Dajnowiec was an employee of Janssen Inc. at the time of manuscript development and is currently an employee of Edwards Lifesciences Corp. Martin Williamson is an employee and shareholder of Janssen Inc. Bernie Sattin is an employee and shareholder of Janssen Inc. EVERSANA is a paid consultant of Janssen and supported in the writing and submission of this manuscript.

Compliance with Ethics Guidelines

Use of the Optum CDM was reviewed by the New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this study used appropriately de-identified data without access to personal identifying information.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Bernie Sattin.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 262 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stewart, M.J., Bessissow, T., Gregor, J. et al. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Adv Ther 38, 4115–4129 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Adalimumab
  • Anti-TNFα biologics
  • Golimumab
  • Healthcare resource utilization
  • Propensity score matching
  • Real-world evidence
  • Treatment patterns
  • Ulcerative colitis